Page last updated: 2024-09-03

profenamine hydrochloride and Myasthenia Gravis

profenamine hydrochloride has been researched along with Myasthenia Gravis in 2 studies

*Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. [MeSH]

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dohnal, V; Dolezal, M; Holas, O; Hrabinova, M; Komloova, M; Kuca, K; Musilek, K; Nachon, F; Pohanka, M	1
Dohnal, V; Gunn-Moore, F; Holas, O; Horova, A; Komloova, M; Kuca, K; Musilek, K	1

Other Studies

2 other study(ies) available for profenamine hydrochloride and Myasthenia Gravis

Article	Year
Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment. European journal of medicinal chemistry, 2011, Volume: 46, Issue:2 Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Erythrocytes; Humans; Isoquinolines; Models, Molecular; Molecular Structure; Myasthenia Gravis; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship	2011
Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment. Bioorganic & medicinal chemistry letters, 2011, Apr-15, Volume: 21, Issue:8 Topics: Acetylcholinesterase; Ambenonium Chloride; Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Edrophonium; Humans; Kinetics; Molecular Dynamics Simulation; Myasthenia Gravis; Protein Binding; Quinolinium Compounds; Recombinant Proteins; Structure-Activity Relationship	2011

Article

Year

Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.

European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Erythrocytes; Humans; Isoquinolines; Models, Molecular; Molecular Structure; Myasthenia Gravis; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship

2011

Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.

Bioorganic & medicinal chemistry letters, 2011, Apr-15, Volume: 21, Issue:8

Topics: Acetylcholinesterase; Ambenonium Chloride; Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Edrophonium; Humans; Kinetics; Molecular Dynamics Simulation; Myasthenia Gravis; Protein Binding; Quinolinium Compounds; Recombinant Proteins; Structure-Activity Relationship

2011